Stocks · News reference
Wells Fargo analyst Yanan Zhu maintains Metagenomi Therapeutics (NASDAQ:MGX) with a Overweight and lowers the price target from $9 to $7.
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Metagenomi (NASDAQ:MGX) reported quarterly losses of $(0.73) per share which missed the analyst consensus estimate of $(0.57) by 28.07 percent. This is a 35.19 percent decrease over losses of $(0.54) per share from the
Read original at benzingaFiled: 2026-08-10 AccNo: 0001193125-26-342388 Size: 364 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgar